GlaxoSmithKline Receives “Buy” Rating from Societe Generale (GSK)
GlaxoSmithKline (LON:GSK)‘s stock had its “buy” rating reaffirmed by equities research analysts at Societe Generale in a research note issued to investors on Tuesday, American Banking News reports. They currently have a GBX 2,000 ($32.27) price objective on the stock. Societe Generale’s price target points to a potential upside of 28.41% from the stock’s previous close.
A number of other firms have also recently commented on GSK. Analysts at AlphaValue reiterated a “sell” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Thursday, September 26th. They now have a GBX 1,440 ($23.23) price target on the stock. Separately, analysts at Panmure Gordon reiterated a “buy” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Tuesday, September 24th. They now have a GBX 1,850 ($29.85) price target on the stock. Finally, analysts at Bank of America Corp. reiterated a “buy” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Monday, September 23rd. They now have a GBX 2,050 ($33.08) price target on the stock. Five research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of GBX 1,640.28 ($26.46).
GlaxoSmithKline (LON:GSK) traded up 1.98% during mid-day trading on Tuesday, hitting GBX 1588.3494. The stock had a trading volume of 6,508,935 shares. GlaxoSmithKline has a 52 week low of GBX 1314.00 and a 52 week high of GBX 1816.00. The stock has a 50-day moving average of GBX 1652. and a 200-day moving average of GBX 1640.. The company’s market cap is £76.956 billion.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.